EarningsGroup revenues saw a decline of 6% to £25.2 million, signaling potential challenges in maintaining sales growth.
Financial PerformanceOverall group sales decreased as a result of deliberate reduction in low-margin products and ending certain operations, which may impact profitability.
Product SalesSales of Point of Care products and other revenues suffered due to the discontinuation of the STAT-Site M β-HB analyser and the exit from the low-margin clinical chemistry business, indicating a shift in product strategy.